Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
14.07
+0.39 (2.85%)
At close: May 27, 2026, 4:00 PM EDT
14.05
-0.02 (-0.14%)
After-hours: May 27, 2026, 7:32 PM EDT
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Amylyx Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $23.4. The average 1-year stock price forecast is 66.31% higher than the current stock price, while the lowest is $19 (+35.04%) and the highest is $34 (+141.65%).
Price Target: $23.4 (+66.31%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 11 | 11 | 11 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $24 | Buy | Maintains | $24 | +70.58% | May 16, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Reiterates $21 | Buy | Reiterates | $21 | +49.25% | May 11, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $30 | Buy | Reiterates | $30 | +113.22% | May 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $34 | Buy | Maintains | $34 | +141.65% | May 8, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $22 | Buy | Reiterates | $22 | +56.36% | May 8, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
45.58M
EPS This Year
-1.49
from -1.53
EPS Next Year
-1.41
from -1.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 132.0M | ||||||
| Avg | n/a | 45.6M | ||||||
| Low | n/a | 2.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.41 | -0.93 | ||||||
| Avg | -1.49 | -1.41 | ||||||
| Low | -1.59 | -1.67 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.